The recent expansion of SARS-COV-2 vaccines is generating an important debate about the immunity they generate against the virus, and knowing whether vaccines are effective is obviously of great concern to the population. The way to corroborate whether these vaccines have the desired effect by provoking the expected immune response is to check whether antibodies...

This collaborative action is part of a broader agreement reached between CIC bioGUNE and BIOLAN in areas aimed at disease diagnosis and other health applications. CIC bioGUNE -a member of the Basque Research & Technology Alliance, BRTA- and BIOLAN have signed a collaboration agreement to exchange the knowledge necessary for the development, manufacture and commercialisation...

The Basque SME located in Zamudio has invested heavily to equip itself with the equipment that will allow it to scale up the newly developed product.  Since January, BIOLAN has had a new product developed and validated with excellent results in terms of sensitivity (96%) and specificity (93%) and with all the necessary requirements for...

BIOLAN HEALTH has completed the validation of its new Serological COVID-19 IgG/IgM Rapid Test Cassette that allows the rapid, simple and accurate detection of antibodies against SARS-CoV-2 in people who are or have been infected by the virus that causes COVID-19. The validation of the test has been successful and confirms a sensitivity of 96%...

A new serological test to detect IgG and IgM antibodies against SARS-CoV-2 has been developed by BIOLAN HEALTH. It is a rapid and easy to use test that, from a drop of capillary blood, will identify people who are or have been infected by the virus that causes COVID-19. A very distinctive feature of the...

A new phase has begun for OSASEN, which in addition to changing its name to BIOLAN HEALTH, with the consequent change of image, has also reinforced its organisational structure with the appointment of Dr. Larraitz Añorga as General Manager. The change of company name and commercial name to BIOLAN HEALTH aims to reinforce its identity...

BIOLAN, through OSASEN, its health division, and CIC bioGUNE -member of the Basque Research & Technology Alliance and BRTA- have initiated a collaboration that will allow the market launch of a new serological test, the OSAtest-IgG/IgM, which allows the rapid, simple and accurate detection of antibodies against SARS-CoV-2 in people who are or have been...

OSASEN’s degree of specialisation in the research and development of Point of Care (PoC) devices and systems based on biosensors with application to in vitro diagnosis includes the possibility of developing rapid tests that facilitate the diagnosis and monitoring of the disease. In this sense, OSASEN is working on the application of its technology to...

Maitane Urien, Biotechnologist at OSASEN, specialising in the development and application of enzymatic biosensors for the diagnosis and monitoring of diseases and therapies, has received the diploma for the best qualification of her class in the master’s degree in biomedical research, which she has completed at the UPV/EHU. Graduating with honours is something that rarely...